• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用 sPSA 预测初诊前列腺癌患者骨扫描结果:在亚洲人群中的可行性。

Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.

机构信息

Department of Diagnostic Radiology and Organ Imaging, United Christian Hospital, Hong Kong, China.

出版信息

Urol Oncol. 2011 May-Jun;29(3):275-9. doi: 10.1016/j.urolonc.2009.05.007. Epub 2009 Sep 6.

DOI:10.1016/j.urolonc.2009.05.007
PMID:19734069
Abstract

OBJECTIVE

A number of large-scaled studies done in Western countries have proven a positive relationship between serum prostate-specific antigen (PSA) level and prevalence of positive bone scan findings in newly diagnosed prostate cancer (CaP) patients. The objective of this study is to verify that the tendency occurs as well in Asian population, as well as to establish a possible correlation between PSA level, bone scan result, and Gleason score.

METHOD

Records of 116 patients diagnosed to have CaP were reviewed retrospectively for bone scan results, PSA levels, and Gleason score.

RESULT

Thirty-four patients were proven to have bone metastases based on positive bone scintigraphy result. None of these patients had a PSA level of less than 10 ng/ml. Two patients had PSA level between 11 and 20, and 15 patients had PSA level between 21 and 200. For patients with PSA level over 201, 17 had bone metastases on bone scintigraphy.

CONCLUSION

Based on the PSA level, the likelihood of positive bone scintigraphy result can be postulated. According to PSA levels, staging investigations can be more selective for patients with confirmed CaP. The risk of having positive bone scan is so low that it is not required for patients with PSA level less than 10 ng/ml. On the other hand, on studying the correlation between Gleason score and PSA level or bone scan results, no statistically significant relationship was established.

摘要

目的

一些在西方国家进行的大规模研究已经证明,在新诊断的前列腺癌(CaP)患者中,血清前列腺特异性抗原(PSA)水平与骨扫描阳性结果之间存在正相关关系。本研究的目的是验证这种趋势是否也存在于亚洲人群中,并确定 PSA 水平、骨扫描结果和 Gleason 评分之间的可能相关性。

方法

回顾性分析了 116 例诊断为 CaP 的患者的骨扫描结果、PSA 水平和 Gleason 评分记录。

结果

34 例患者经骨闪烁扫描证实有骨转移。这些患者的 PSA 水平均低于 10ng/ml。2 例患者的 PSA 水平在 11-20ng/ml 之间,15 例患者的 PSA 水平在 21-200ng/ml 之间。对于 PSA 水平超过 201ng/ml 的患者,17 例在骨扫描上有骨转移。

结论

根据 PSA 水平,可以推测出骨闪烁扫描阳性结果的可能性。根据 PSA 水平,可以对确诊的 CaP 患者进行更有选择性的分期检查。PSA 水平低于 10ng/ml 的患者发生骨扫描阳性的风险很低,因此不需要进行骨扫描。另一方面,在研究 Gleason 评分与 PSA 水平或骨扫描结果之间的相关性时,没有建立统计学上的显著关系。

相似文献

1
Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.应用 sPSA 预测初诊前列腺癌患者骨扫描结果:在亚洲人群中的可行性。
Urol Oncol. 2011 May-Jun;29(3):275-9. doi: 10.1016/j.urolonc.2009.05.007. Epub 2009 Sep 6.
2
[Bone scan findings in a North African ethnic group and relation to PSA level and Gleason score of the biopsy].[一个北非种族群体的骨扫描结果及其与活检时前列腺特异性抗原(PSA)水平和 Gleason 评分的关系]
Actas Urol Esp. 2011 Oct;35(9):534-9. doi: 10.1016/j.acuro.2011.03.013. Epub 2011 Jun 12.
3
[Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].[前列腺特异性抗原和Gleason评分对前列腺癌患者放射性核素骨显像结果的预测价值]
Beijing Da Xue Xue Bao Yi Xue Ban. 2012 Aug 18;44(4):528-34.
4
Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.初次前列腺特异性抗原检测能否消除新诊断前列腺癌患者进行骨扫描的必要性?一项在日本开展的多中心回顾性研究。
Cancer. 2002 Feb 15;94(4):964-72.
5
Is bone scintigraphy necessary in initial staging of prostate cancer patients?骨闪烁显像对于前列腺癌患者的初始分期是否必要?
Hell J Nucl Med. 2011 May-Aug;14(2):126-30.
6
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.初诊前列腺癌患者何时行骨扫描:当前可用指南的外部验证及新型风险分层工具的提出。
Eur Urol. 2010 Apr;57(4):551-8. doi: 10.1016/j.eururo.2009.12.023. Epub 2009 Dec 18.
7
Prostate specific antigen level and Gleason score in predicting the stage of newly diagnosed prostate cancer.前列腺特异性抗原水平和 Gleason 评分在预测新诊断前列腺癌分期中的作用
Br J Radiol. 1998 Nov;71(851):1130-5. doi: 10.1259/bjr.71.851.10434906.
8
Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.血清前列腺特异性抗原作为新诊断前列腺癌影像学分期研究的预测指标。
Cancer Invest. 1995;13(1):31-5. doi: 10.3109/07357909509024892.
9
Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.无症状且未经治疗的前列腺癌患者治疗前分期中骨转移的预测因素
Rev Esp Med Nucl Imagen Mol. 2013 Sep-Oct;32(5):286-9. doi: 10.1016/j.remn.2013.01.002. Epub 2013 Mar 9.
10
Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan.用于预测日本前列腺癌患者是否需要进行放射性核素骨扫描的前列腺特异性抗原、Gleason评分总和及临床T分期
Int J Urol. 2005 Aug;12(8):728-32. doi: 10.1111/j.1442-2042.2005.01118.x.

引用本文的文献

1
Evaluation of selective bone scan staging in prostate cancer - external validation of current strategies and decision-curve analysis.前列腺癌选择性骨扫描分期评估——当前策略的外部验证及决策曲线分析
Prostate Cancer Prostatic Dis. 2022 Feb;25(2):336-343. doi: 10.1038/s41391-022-00515-8. Epub 2022 Mar 14.
2
JPX and LINC00641 ncRNAs expression in prostate tissue: a case-control study.前列腺组织中JPX和LINC00641非编码RNA的表达:一项病例对照研究。
Res Pharm Sci. 2021 Aug 19;16(5):493-504. doi: 10.4103/1735-5362.323916. eCollection 2021 Oct.
3
Establishing a prediction model for prostate cancer bone metastasis.
建立前列腺癌骨转移预测模型。
Int J Biol Sci. 2019 Jan 1;15(1):208-220. doi: 10.7150/ijbs.27537. eCollection 2019.
4
When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study.新诊断前列腺癌患者何时进行骨闪烁显像?一项回顾性研究。
BMC Urol. 2017 Jun 12;17(1):41. doi: 10.1186/s12894-017-0229-z.
5
Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.使用一线雄激素剥夺疗法治疗的转移性前列腺癌TNM分类的验证
World J Urol. 2016 Feb;34(2):261-7. doi: 10.1007/s00345-015-1607-3. Epub 2015 Jun 6.
6
Prostatic metastases and polycythemia vera on bone magnetic resonance imaging: A case report.骨磁共振成像显示前列腺转移和真性红细胞增多症:一例报告。
Oncol Lett. 2015 Mar;9(3):1317-1320. doi: 10.3892/ol.2014.2809. Epub 2014 Dec 17.
7
Application of bone scans for prostate cancer staging: Which guideline shows better result?骨扫描在前列腺癌分期中的应用:哪种指南显示出更好的结果?
Can Urol Assoc J. 2014 Jul;8(7-8):E515-9. doi: 10.5489/cuaj.2054.
8
When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool.初诊前列腺癌患者何时行骨扫描:新型风险分层工具的外部验证。
World J Urol. 2013 Apr;31(2):365-9. doi: 10.1007/s00345-012-0880-7. Epub 2012 May 11.
9
Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?对于 PSA≤20ng/mL 的前列腺癌患者,是否适合消除骨扫描?
World J Urol. 2012 Apr;30(2):265-9. doi: 10.1007/s00345-011-0728-6. Epub 2011 Jul 16.